title: Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
abstract: OBJECTIVE
  The aim of this study was to assess the impact of switching from immediate-release (IR) methylphenidate (MPH) to OROS MPH (CONCERTA, a once-daily long-acting MPH formulation, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
  
  
  METHODS
  Subjects with ADHD aged 6-16 (n=105),who were stably maintained on their current IR MPH regimen (10-60 mg/day), were switched to 18, 36 or 54 mg OROS MPH once daily for 21 days, depending on pre-study daily MPH dose. ADHD symptoms were assessed by parents, teachers and investigators.
  
  
  RESULTS
  By Day 21, parent/caregiver IOWA Conners ratings had decreased from baseline by 2.7 points to 5.2 (I/O), and by 1.8 points to 5.0 (O/D). Teacher IOWA Conners ratings were maintained. Decreases in IOWA Conners ratings are indicative of ADHD symptom improvement. Approximately 75% of parents and investigators rated therapy as good or excellent. OROS MPH therapy was well tolerated.
  
  
  CONCLUSIONS
  Switching from IR MPH to OROS MPH maintained and may have improved symptom control in children and adolescents with ADHD, during the course of this study. The changes in parent/caregiver IOWA Conners ratings suggest that OROS MPH improves symptom control in the after-school period. This is consistent with the 12-h duration of action previously demonstrated for OROS MPH.
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie, Hans-Sachs-Strasse 6, 35033 Marburg, Germany. remschm@med.uni-marburg.de
authors.forename: H
authors.initials: H
authors.lastname: Remschmidt
authors.forename: P
authors.initials: P
authors.lastname: Hoare
authors.forename: C
authors.initials: C
authors.lastname: Ettrich
authors.forename: A
authors.initials: A
authors.lastname: Rothenberger
authors.forename: P
authors.initials: P
authors.lastname: Santosh
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: Q
authors.initials: Q
authors.lastname: Spender
authors.forename: R
authors.initials: R
authors.lastname: Tamhne
authors.forename: M
authors.initials: M
authors.lastname: Thompson
authors.forename: C
authors.initials: C
authors.lastname: Tinline
authors.forename: G E
authors.initials: GE
authors.lastname: Trott
authors.forename: R
authors.initials: R
authors.lastname: Medori
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage* / Q000009:adverse effects; D010552:Personality Assessment; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate